- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Mol Med Rep. 2015 Dec 7. doi: 10.3892/mmr.2015.4654. [Epub ahead of print]
Dendritic cells pulsed with Hsp70 and HBxAg induce specific antitumor immune responses in hepatitis B virus‑associated hepatocellular carcinoma.Wang H1, Feng F1, Wang XP1, Wang RS1, Wu Y1, Zhu MG1, Zhang H1, Zhuang ZX1.
Author information
- 1Department of Oncology, The Second Affiliated Hospital, Soochow University, Suzhou, Jiangsu 215004, P.R. China.
AbstractPrevious studies have drawn attention to dendritic cell (DC) vaccines; particularly the application of the tumor‑associated antigen‑targeted DC vaccine. The present study analyzed DCs derived from a normal individual and pulsed the cells with heat shock protein 70 peptide (Hsp70) and/or hepatitis B virus x antigen (HBxAg), a hepatocellular carcinoma (HCC)‑associated antigen. It was then investigated whether this method of vaccination induced strong therapeutic antitumor immunity. The results revealed that the Hsp70/HBxAg complex‑activated phenotype improves the functional maturation of DCs compared with using Hsp70 or HBxAg alone. Compared with either Hsp70 or HBxAg alone, matured DCs pulsed with the Hsp70/HBxAg complex stimulated a high level of autologous T‑cell proliferation and induced HCC‑specific cytotoxic T lymphocytes, which specifically killed HCC cells through a major histocompatibility complex class I mechanism. These results indicated that a vaccination therapy using DCs co‑pulsed with the Hsp70/HBxAg complex is an effective strategy for immunotherapy and may offer a useful approach to protect against HCC.
|
|